Osteoporotic fractures impose severe physical, psychosocial, and financial burden both to the patient and the society. Studies on the prevalence of osteoporosis and fragility fractures in Brazil show a wide variation, due to differences in sample size, the population studied, and methodologies. Few studies have been conducted in Brazil about the cost-effectiveness analyses of different intervention options aimed at the diagnosis and treatment of osteoporosis. Investigation and treatment strategies based on cost-effectiveness and scientific evidence are essential in the preparation of public health policies with the ultimate goal of reducing the incidence of fractures and, consequently, the direct and indirect costs associated with them. This article reviews the Brazilian burden of osteoporosis in terms of the prevalence and fractures attributable to the disease, the costs related to the investigation and management, as well as the impact of osteoporosis on the population as a whole and on affected individuals. Arq Bras Endocrinol Metab.
INTRODUCTION
O steoporosis is a major health concern with up to 9 million new osteoporotic fractures expected an nually worldwide (1, 2) . Osteoporotic fractures impose severe physical, psychosocial, and financial burden both to the patient and the society. They may be accompanied by pain, bone deformities, fear, distress, difficulty in per forming daily activities, loss of independence, and insti tutionalization (3) . More important, fragility fractures are associated with high mortality rates that can exceed 20% in the first year after the fracture (4, 5) . These de vastating consequences of osteoporotic fractures result in high economic costs to society, as fractures gene rate expenses with medical treatment, surgeries, hospital stays, and rehabilitation. These costs tend to rise with the aging of the population and, consequently, greater prevalence of osteoporosis and its complications (6) .
Osteoporosis is a "silent" disorder until it leads to one or more fractures (7) . Since the treatment of osteo porosis can reduce the fracture risk, the early detection of osteoporosis by the measurement of bone mineral density (BMD) by dualenergy Xray absorptiometry (DXA) should be targeted in clinical practice (8) . In fact, according to the 2002 Brazilian Consensus of Os teoporosis, BMD measurements should be performed in a number of settings -and as a rule, for all women over 65 years of age and men over 70 years (9) .
This article reviews the Brazilian burden of osteo porosis in terms of the prevalence of osteoporosis and fractures attributable to the disease, the costs related to its management and its impact on the population as a whole and on affected individuals.
MATERIALS AND METHODS
We searched for English and Portugueselanguage ar ticles, in human subjects, available in full electronic me dia in MedLine (PubMed) and the database of the Latin American and Caribbean Literature on Health Sciences (LILACS) published within all dates. The search terms used were "osteoporosis" and "Brazil" in addition to one of the following: "costs or expenditure", "burden", "prevalence", "fracture", "quality of life", or "impact". Relevant articles were reviewed in detail. Pertinent data concerning the demographic profile of the Brazilian population were also used. Furthermore, author's work published as an abstract regarding the direct costs re lated to the biochemical workup in the management of osteoporosis was also reviewed (10) .
DEMOGRAPHIC PROFILE OF THE BRAZILIAN POPULATION
According to the 2010 census, conducted by the Ins tituto Brasileiro de Geografia e Estatística (IBGE), the Brazilian population in 2010 was 190,755,799 and ta ble 1 shows our demographic profile in 2000 and 2010. The percentage of elderly individuals increased in 2010 relative to 2000 (11) and consequently the prevalence of diseases such as osteoporosis is expected to rise. In 2010, there were more than 20 million Brazilians over 65 years of age, and the projection for this segment of the population is to exceed 50 million by 2050 (11, 12) . Moreover, 20.45% of the population was older than 50 years in 2010. Women over 65 years of age accounted for 4.18% of the population, while men over 70 years of age corresponded to 2.04% (Table 1) (11, 12) . 
PREVALENCE OF OSTEOPOROSIS IN BRAZIL
In Latin America, the estimated prevalence of spine os teoporosis in women aged 50 years and more ranges from 12.1% to 17.6%, while that of femoral neck os teoporosis ranges from 7.9% to 22% (13) . Brazil is a country of extensive race mixing and heterogeneous re gional distribution, which implies different risk factors for osteoporosis and fractures (14) . Moreover, access to BMD testing, which is essential for the detection of osteoporosis and intervention before fracture occurs, is still sparse in Brazil. The poor instrument availabili ty, high cost to patients and restrictive indications for BMD testing constitute the major barriers for the access to such testing in Brazil. Despite these limitations, few studies have evaluated the prevalence of osteopenia and osteoporosis in Brazil, which shows a wide variation, due to differences in sample size, eligibility criteria, and methodologies, as showed in table 2 (15) . Overall, the prevalence of osteoporosis in Brazilian studies ranges from 6% to 33% depending on the population and other variables evaluated (1618). Baccaro and cols. have evaluated, by questionnaire, the prevalence of osteoporosis and its associated fac tors in 622 Brazilian women over 50 years of age. The preva lence of selfreported osteoporosis was 21.3% (19) . Using BMD for diagnosis, in 2011, Buttros and cols., found in a crosssectional study 24.6% of osteo porosis and 43.6% of osteopenia in 431 postmeno pausal women (aged 40 -75 years) evaluated (20) . The São Paulo Osteoporosis Study (SAPOS) estimated the prevalence of osteoporosis and lowtrauma fracture in 4,332 women over 40 years of age. BMD at the lumbar and femoral sites was measured by DXA in all partici pants, and the prevalence of osteoporosis was 33% (18) . able in Latin America and Brazil. A review of Latin American studies showed that the incidence of osteopo rotic hip fractures ranged from 40 to 362 per 100,000 persons of 50 years or older, with a femaletomale ratio of 3:1. The majority of the studies showed lower inci dence of hip fractures in the Latin American population compared with the population of the United States, Canada, and Europe. This discrepancy was likely due to differences in the studied population, the adopted definition of case, and methodological issues (13) .
The Latin American Vertebral Osteoporosis Study (LAVOS) evaluated a randomized sample of 1,922 women aged 50 years and older from Argentina, Brazil, Colombia, Mexico, and Puerto Rico (22) . The preva lence of vertebral fractures as assessed by lateral Xrays of the lumbar and thoracic spine was 11.18%, and was similar in the five countries. Among women aged 50 to 59 years, the prevalence was 6.9%, which increased to 27.8% for those aged 80 years or older.
Studies exclusively conducted in Brazil show that the incidence of osteoporotic fractures varied with the population and the fracture site investigated. Overall, the ageadjusted annual incidence of fractures varied from 5.59 to 13 per 10,000 in women, and from 12.4 to 27.7 per 10,000 in men (16) . The lowest incidences of fractures in the above ranges, both in women and men, correspond to the incidence of hip fractures in Sobral, a city located in the Northeast Region of Brazil (3ºS/40ºE) (23) .
In BRAZOS, 2,420 Brazilian individuals from the five geographic regions of the country were evaluated. The prevalence of selfreported fragility fractures de fined as that resulting of any fall from standing height or less in subjects > 40 years old, was 12.8% in men and 15.1% in women. Statistically significant differences among Brazilian regions, according to gender or social class, were not observed (24). The overall prevalence of osteoporosis appears to be lower when women and men are included in the evalua tion. The Brazilian Osteoporosis Study (BRAZOS), which evaluated a representative sample of 2,420 Bra zilian individuals (women, 70%) > 40 years old, from different regions and economic classes revealed that the selfreported prevalence of osteoporosis was only 6% (16). Camargo and cols. assessed the BMD of 301 in dividuals (207 women) older than 70 years of age from different clinical centers in the city of São Paulo. The prevalence of osteoporosis ranged from 6.4% to 16.1% in men, and from 22.2% to 33.2% in women in the dif ferent centers studied (17) .
Another crosssectional study conducted in São Pau lo evaluated 2,143 subjects ≥ 60 years old interviewed in the years of 2000 and 2006 (21) . The prevalence of osteoporosis, assessed by selfreport, was greater among subjects with private health insurance coverage than in those without private insurance, regardless of sex and year of evaluation. This finding may represent a wider access to DXA tests and better understanding of the disease among those with private health insurance.
Finally, in a crosssectional study based on data from the VIGITEL system (Risk Factor Surveillance and Pro tection against Chronic Diseases through Telephone Survey) conducted in 2006, 54,369 Brazilian indivi duals (33,075 women) > 18 years of age were interviewed. The prevalence of osteoporosis as assessed by self report was 4.4% in the entire population, 7% in women and 1.3% in men (12) . This lower prevalence of osteoporosis as compared to the previous studies reported here may be explained by the low age of subjects included.
INCIDENCE AND PREVALENCE OF OSTEOPOROTIC FRACTURES
There are few consistent data on the prevalence and rele vance of risk factors for osteoporotic fracture avail Siqueira and cols. evaluated the prevalence of self reported fractures and its association with sociodemo graphic variables and medical diagnosis of osteoporosis in 3,100 individuals from Pelotas, a Southern Brazilian city (56.6% women) (25) . The lifetime prevalence of any type of fracture was 37.5% among men and 21.3% among women (P < 0.001). While in men most fractures were caused by sports practice and happened in leisure time, most fractures in women were caused by falls and occurred inside the home. The prevalence of fractures throughout life was almost twice as higher (28.3%) than that observed in the BRAZOS study (14.4%) (24, 25) . It is important to emphasize that individuals aged 20 years or more were included in Siqueira's study, as well as traumarelated and nontraumatic fractures.
In the SAPOS study, the prevalence of selfreported osteoporotic fractures was 11.5%, with a mean age of 65.5 ± 10 years at the time of the event. Among the 497 women with fractures, vertebral fractures were re ported in 6%, nonvertebral fractures in 86% (including the humerus, distal forearm, metacarpus, ribs, and hip) and femoral fractures in 8% of the cases (18) .
A crosssectional study conducted in Chapecó, a Southern Brazilian city, explored the prevalence of as ymptomatic vertebral fractures by radiographs, in a pop ulation of 186 postmenopausal women over 60 years (26) . Almost half of the women studied (48.9%) had at least one vertebral fracture not associated with a prior history of fracture. The higher prevalence of vertebral fractures in this study was mainly attributed to the crite ria used for the analysis and definition of vertebral frac tures, the population studied (all subjects were white), the high frequency of risk factors such as glucocorticoid use, low dietary calcium intake, and alcohol abuse, and the latitude of the city (below the equator) (26) .
In the city of São Paulo, Lopes and cols. evaluated 1,007 elderly subjects (600 women) using BMD test ing of hip and lumbar spine (27) . The prevalence of osteoporotic fractures assessed by selfreport was 13.2% and the major sites affected were distal forearm (6.0%), humerus (2.3%), femur (1.3%), and ribs (1.1%). Wo men had greater prevalence of fractures (17.5%) com pared with men (6.9%) (27) .
In the city of Campinas, Baccaro and cols. evalu ated 622 women aged 50 years or older and the overall prevalence of selfreported bone fragility fractures was 10.8%, whereas the prevalence of femoral/hip fractures was 1.8%. In the multiple regression analysis, a higher prevalence of fragility fractures was associated with a longer time since the menopause and the presence of osteoporosis (19) .
IMPACT OF FRAGILITY FRACTURES ON THE INDIVIDUAL
Osteoporosis poses a significant negative impact on the quality of life of patients, particularly after fragility frac tures, which is supported by the majority of the studies reviewed below.
Osteoporotic fractures, commonly of the hip and spine, often result in secondary complications, such as functional impairment, increased hospital stays that may result in further health problems, increased medi cal costs, and increased dependence on others for living assistance (28) . In addition to the evident physical and functional consequences, such as kyphosis, restriction of movement, and pain, the individual with osteoporo sis may sustain a psychosocial impact. Many patients, in the early stages of the disease, express marked anxiety, especially regarding the possibility of future fractures and physical deformity. As the disease progresses, de pression may be aggravated for those who sustain hip fractures or multiple vertebral fractures. Osteoporosis can lead to dependence, functional disability, and low ered selfesteem (29) . Among Brazilian women over 45 years of age, 84% are concerned about having osteo porosis, and 13% of them have sustained at least one fragility fracture after the age of 40. Among women who had fractures, 52% reported worsened quality of life following the fracture (29) .
The BRAZOS study showed a strong association between poor quality of life and the presence of low impact fractures, both in men and women older than 40 years of age, emphasizing that patients with osteo porosis and fractures have a higher incidence of chronic pain, decreased physical capacity, reduction in social activities, decreased perception of well being, and de pressed mood than individuals without fractures (16) .
In a study that evaluated 56 elderly patients ≥ 60 years old with a lowtrauma hip fracture, from the Bra zilian city of São Paulo, there was an increase in the inability to walk and in the use of a supporting device. The hip fracture also led to a significant reduction in the functional ability to perform basic and instrumental activities of daily living (30) .
Even asymptomatic vertebral fractures can negative ly impact the quality of life. In a Brazilian crosssection al study including 180 women aged 65 years and older with or without vertebral fractures, the quality of life was assessed by the European quality of life question naire (Quality of Life Questionnaire of the European Foundation for Osteoporosis -QUALEFFO41) (31) . The presence of asymptomatic vertebral fractures iden tified on thoracic and lumbar spine radiographs was as sociated with a reduced quality of life regardless of age, BMI, and level of physical activity (31) .
Another study assessed the prevalence and the as sociation between the number of vertebral fractures and quality of life in 126 postmenopausal Brazili an osteoporotic women (mean age 65.7 years). The prevalence of vertebral fractures identified on thoracic and lumbar spine radiographs was 34.1%. While the QUALEFFO41 questionnaire showed no difference in scores between women with and without vertebral fractures, there was a direct correlation between the quality of life score and the number of vertebral frac tures (32) .
Fortes and cols. evaluated the morbidity and mor tality deriving from proximal femoral fractures in in dividuals over 60 years of age who were admitted to two hospitals in the city of São Paulo (33) . A marked decrease was noted in the indicators of functional dis ability evaluated using the Health Assessment Ques tionnaire (HAQ), after six months of the fracture event.
The factors that correlated with poorer functional abili ty were HAQ score prior to fracture, institutionaliza tion after fracture and age. Six months after the event, 11.6% of the patients had become completely depen dent and 9.3% were institutionalized (33) .
IMPACT OF OSTEOPOROSIS AND FRAGILITY FRACTURES ON SOCIETY Mortality
Hip fracture is one of the most feared consequences of osteoporosis. Hip fractures are associated with high post fracture disability, increased mortality, and high healthcare expenditures (34) . The mortality rate from hip fractures in developed countries is around 25% in the first year after the event (4, 5) . Mortality rates dur ing the hospitalization period range from 1.02% to 10% across countries (13) .
In Brazil, it is estimated that 15% to 30% of patients with hip fractures die within the first year following the event, frequently as a result of fracture complications such as infections, venous thrombosis, and pressure ul cers, or comorbid conditions, especially cardiovascular diseases. The predominant factors related to increased risk of death are male gender, old age, impaired func tional ability prior to the fracture, greater number of comorbidities, sarcopenia and a fragile phenotype (15) .
A study analyzed the profile of the Brazilian pub lic health care system (SUS)
, which is in disagreement with other Brazilian studies. The proportion of outcomes of death increased with advancing age in the three analyzed years and the Southeast region had the highest percentage of deaths for elderly patients hospitalized with hip fracture (35) .
A prospective study published in 2009 investigated the mortality rate in the first year after hip fractures, as well as the factors associated with mortality in Bra zilian patients. In total, 246 individuals older than 60 years were followed for one year after hospitalization for hip fractures. Eightysix patients died (35%), with most of those deaths (74.4%) occurring after hospital discharge. Of the 67 men, 29 died (43.3%), and of the 179 women, 57 died (31.8%) within the first year af ter fracture. Functional status prior to the fracture, age, male gender, and high surgical risk increased mortality risk, while antibiotics use and physical activity after the surgery reduced the risk (34) .
A similar study conducted in Rio de Janeiro, showed a 21.5% overall mortality in the first year after hip frac tures. Most of those deaths (55.1%) also occurred after hospital discharge, and were chiefly associated with car diovascular events or infections (36) .
Finally, a Brazilian study involving 56 elderly in dividuals from São Paulo showed a mortality rate of 23.2% over the six months following a hip fracture. The most frequent causes of death were infectious (46.1%), cardiovascular (46.1%) or indeterminate (7.8%) (33) .
Besides the impact of osteoporotic fracture, a Bra zilian study linked low BMD with increased cardiovas cular mortality. This prospective cohort of 275 post menopausal elderly women with a 5year followup showed a clear association between low BMD at the femoral sites and increased overall and cardiovascular mortality, regardless of age, weight, body mass index, smoking status, previous fracture, physical activity, drug use, and presence of chronic diseases (37).
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Direct costs
The costs to society can be divided into direct and indi rect, and are related both to the prevention and treat ment of osteoporosis and rehabilitation following the fracture. These costs vary widely between countries, not only due to the varying incidence rates of the dis ease, but also because of the different degrees of em phasis placed on prevention, hospitalization, and treat ment (38) .
Direct costs related to the management of osteoporosis: the biochemical workup
During the investigation of a low BMD, a biochemical workup aimed primarily at the detection of secondary causes of osteoporosis is indicated. The extent of the workup may vary according to the recommendation of each clinical institution or reference Service. Vari ous disorders affecting bone mass are common and of easy diagnosis and treatment. Some tests are key in the investigation of secondary factors that interfere with bone mass, such as serum levels of calcium, parathyroid hormone (PTH), 25hydroxy vitamin D (25OHD), thyroidstimulating hormone (TSH), and 24h urine cal cium. While patients with a clinical suspicion of sec ondary conditions should have extended diagnostic workup, the costs of ordering more complex tests for all patients with osteoporosis have not been estimated (10) .
Several studies have demonstrated the importance of laboratory studies in patients with osteoporosis (39 42) . Our group evaluated the frequency and costeffec tiveness of the tests ordered for postmenopausal women who had been diagnosed as having osteoporosis based on BMD by DXA (10) . The study was conducted in an outpatient clinic of general endocrinology in Belo Horizonte, Brazil, and in total, 185 medical records of postmenopausal women were reviewed. Patients with kidney or liver failure, or known to have a condition or a medication history that could cause bone loss were excluded. Of the 185 patients evaluated, 108 exhibited one or more abnormal tests (126 laboratory abnormali ties) indicative of disorders that could contribute to de creased bone mass or compromise the efficacy of the osteoporosis treatment (Table 3 ) (10) .
In this study, serum calcium was the most frequently ordered test (100% of the patients) (Table 4) ; however, calcium concentrations were outside the reference range in only 9% of the patients (Table 4 ). The 25OHD test, which was ordered for 82% of the patients, was altered in 42% the study population (10) . A high proportion of acromegaly diagnoses was noted (two abnormal tests in five ordered), which might be explained by the fact that the study was conducted in a referral center, where the degree of suspicion of endocrine diseases is high. None of the patients had the diagnosis of Cushing syndrome, and of note, antigliadin antibodies were negative in all patients tested (10) . These findings corroborate what had been published in similar studies in other countries. In the study by Tannenbaum and cols., 1.8% of patients had celiac disease, while 0.6% had Cushing syndrome (42) . Rajeswaran and cols. found 4.23% of patients with celiac disease and no Cushing syndrome (43) . Cushing syndrome accounts for 510 cases/million/year (44) and celiac disease has a prevalence of 1% (45 Direct costs related to the management of osteoporosis: treatment It is estimated that SUS accounts for the provision of healthcare to 75.5% of the Brazilian citizens, and medications represent a sizable fraction of the public spending with health (47) . The expenses of Brazil's Ministry of Health with drugs acting on bone struc ture and mineralization correspond to approximately 10.9% of the total spending with highcost medications (48) . In the São Paulo public health system, in 1998, the mean annual cost for postmenopausal osteoporo sis treatment in ambulatory patients amounted to 775 dollars per patient, and outofthepocket payments by the patients corresponded to 9% of the monthly family income (49) . In Minas Gerais State, Brandao and cols. examined a historical cohort of 72,265 women, mean age 64.8 ± 9.8 years old, who used highcost medi cations supplied by the SUS to treat postmenopausal osteoporosis in the period 2000 to 2006 (50) . The study demonstrated that the mean monthly per capita expenditure in the first year of treatment was 51 USD, and this gradually increased with increasing age from 50 years. The average monthly expenditure was 3.9% greater in women aged 50 to 59 years than in women < 49 years old. Similarly, the monthly expenditure was 55.8% greater in women who had sustained a fragil ity fracture as compared to those without fractures. A total of 6,429 (8.9%) patients died during the study period. The average monthly per capita expenditure was 2.2% higher in women who died than in those who were alive at the end of the study (p = 0.02). The most commonly used drug at the beginning of the treatment was alendronate (57%), followed by calcitonin (24.6%) and raloxifene (15.5%). The type of antiosteoporosis therapy used was the variable with the highest impact on the average monthly per capita expenditure, with tamoxifen and calcitonin having the greatest impact on the mean monthly spending, using alendronate as the standard drug (50) .
Hip fractures typically demand inhospital care, while hospitalization is less frequent in vertebral, wrist, and other fractures (15) . A recent study evaluated the profile of SUS hospitalizations for the treatment of femoral osteoporotic fracture in elderly patients in Brazil between 2006 and 2008 (35) . Over this 3year period, 1% of the senior citizens hospitalized had a femoral fracture as the primary diagnosis. The total spending with hospital stays for femoral fractures in the elder fore, it is likely that these diseases were not found in the present study because of the population sample size (small in relation to the prevalence of these two dis eases, especially Cushing syndrome) and the reduced number of screening tests performed (antigliadin anti body and cortisol levels were measured in 6%, and 9% of the patients, respectively).
In order to assess the costeffectiveness of different testing strategies for the diagnosis of secondary causes of osteoporosis, we further evaluated a subgroup of 62 patients with no treatment for osteoporosis who under went all the tests of a basic workup routine, which were: serum calcium, 24h urine calcium, PTH, 25OHD, and TSH. This workup was selected based on different recommendations of several Societies (7, 40, 42, 43, 46) . The strategy of ordering PTH, 24h urine calcium and 25OHD for all patients, and TSH for those in use of le vothyroxine, resulted in 100% of diagnoses at a cost of 69.7 U.S. dollars (USD) per patient screened and 84.7 USD per diagnosis. The testing strategy that proposes ordering PTH and 24h urine calcium measurements for all patients, 25OHD for those with an abnormal PTH and/or urinary calcium, and TSH for the levo thyroxine users identifies 84.31% of the disorders at a lower cost, of 55.6 USD per patient and 80.2 USD per diagnosis (10). The current cost of different diagnostic tests for osteoporosis in Brazil is depicted in table 5. This number is closer to direct hospitalrelated costs re ported in other countries, which suggests that the costs calculated by the hospitals with an agreement with the SUS are lower than the actual cost of the treatment for acute femur fracture. Femoral fractures were ob served in 4.99% of the 129,611 cases of osteoporosis managed within the private healthcare system. The an nual economic burden of these fractures for the health insurance companies was estimated in approximately 6 million USD (15, 52) . However, these results do not provide consistent data on the total costs over the me dium and long term (15) . Regarding pharmacoeconomic analyses, a Brazilian study performed a systematic review of the strategies used in Brazil and worldwide, focusing on the treat ment of osteoporosis in postmenopause. The use of bisphosphonates was the most extensively evaluated strategy, and produced the best costeffectiveness. Hor mone therapy, calcium and vitamin D supplementation, strontium ranelate, raloxifene, teriparatide, and deno sumab were also evaluated, with varying outcomes. Given the particularities of the Brazilian context, it was impossible to extrapolate any of the external results to our population, which restricted the applicability of such results to the decisionmaking process in public health policies (38) .
Costeffectiveness analyses of different interven tion options aimed at the diagnosis and treatment of osteoporosis, with the ultimate goal of reducing the in cidence of fractures and, consequently, the direct and indirect costs associated with them, are paramount in the preparation of public health policies. Few studies have been conducted in Brazil in this regard. In 2003, Silva and cols., using the decision tree tool, calculated in 34,800.00 USD the cost per fracture that could be spared if the BMD/alendronate intervention were ap plied to women over 65 years of age, and in 4,315.00 USD if only the association of calcium and vitamin D were used (53) . Both estimates far exceeded the mean cost to treat femoral fractures (750.00 USD) estimated from DATASUS 2001 data, which led the authors to question the indication to implement any prevention and treatment strategy, given the limited resources. The analysis that those authors undertook was pre liminary and shows methodological shortcomings, yet it reinforces the need for enhanced knowledge of cost analysis strategies in our setting. In 2008, Araújo and cols. evaluated the costeffectiveness of the osteoporosis treatment with zoledronic acid in the Brazilian private healthcare system, in a hypothetical cohort of women over 65 years of age using the Markov model (54) . The use of zoledronic acid has proved to be costeffective in the prevention of proximal femur fracture in that spe cific setting; however, these data cannot be extrapolated to the public system or to other sites of osteoporotic fractures. Additionally, the use of new tools enabling the calculation of individual risks of fracture based on clini cal estimators, such as FRAX Brazil (Fractures Risk As sessment) and SAPORI (São Paulo Osteoporosis Risk Index), could contribute to a more effective use of the available diagnostic and therapeutic resources (55) .
Indirect costs
In addition to imposing direct medical costs to soci ety, osteoporosis also entails indirect costs, especially those related to reduced productivity, disability and early deaths. It is difficult to measure and evaluate the impact of indirect costs. One method quantifies loss of productivity based on profit reduction. Considering that bone diseases affect a large number of retired in dividuals, indirect costs are underestimated by this ap proach. Howe ver, assuming that people are worth what they earn, a study estimates that the cost of premature deaths and restricted activities resulting from fractures account for 26% of the total cost with fractures, and 12% of the costs deriving from hip fractures (7) . In Bra zil, there are no studies assessing the specific burden of the indirect costs of osteoporosis on society.
CONCLUSIONS
Osteoporosis is a disabling disease associated with high rates of morbidity and mortality. The projected number of individuals with osteoporosis in Brazil will increase as the population ages, which may have serious economic impact on our society and on the quality of life of the affected individuals.
In spite of the heterogeneity of Brazilian studies, the overall prevalence of osteoporosis and fragility frac tures in our country is high. In addition to the different ways to assess osteoporosis (e.g. selfreport vs. DXA), the sociodemographic characteristics of our population also influence the results found.
There are few Brazilian studies of costeffectiveness strategies used in the workup and treatment of osteopo rosis. Nonpharmacological strategies should always be considered, however without neglecting the proven ef ficacy of the various pharmacological options available. Early detection and sensible use of antifracture medi cations are invaluable in reducing the morbidity and mortality deriving from fractures. More comprehensive, multicentric studies are needed to enable us to outline evaluation and treatment protocols for our population.
Public policies aiming at the education of the popu lation regarding the importance of osteoporosis pre vention, which should be initiated in childhood and adolescence, could minimize the future economic bur den of the disease.
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